

CONVERSION OF PROSTAGLANDIN ENDOPEROXIDES TO C₁₇-HYDROXY ACIDS CATALYZED BY HUMAN PLATELET THROMBOXANE SYNTHASE

Ulf DICZFALUSY, Pierre FALARDEAU* and Sven HAMMARSTRÖM

Department of Chemistry, Karolinska Institutet, S-104 01 Stockholm, Sweden

Received 14 October 1977

1. Introduction

Thromboxane A₂ is a new, unstable bioregulator which induces the platelet release reaction, platelet aggregation and smooth muscle contractions [1]. An enzyme catalyzing the conversion of prostaglandin endoperoxides to thromboxanes (thromboxane synthase) has been isolated from platelet microsomes [2] and the inhibition of this enzyme by various compounds has been investigated [3]. In addition to thromboxane (TX)B₂, 12L-hydroxy-5,8,10-heptadecatrienoic acid (HHT) was enzymatically formed from prostaglandin (PG)H₂ by platelet microsomes and purified thromboxane synthase [2]. The present paper provides evidence that TXB₂ and HHT are formed by the same enzyme. It also shows that the formation of IHHT does not involve TXA₂ as an intermediate.

2. Materials and methods

Human platelet microsomes, partially purified

Abbreviations: APA, 9 α ,11 α -azo-15(S)hydroxyprosta-5(*cis*)-13(*trans*)-dienoic acid; EMPA, 9 α ,11 α -epoxymethano-15(S)hydroxyprosta-5(*cis*)-13(*trans*)-dienoic acid; GLC-MS, gas-liquid chromatography - mass spectrometry; HHT, 12L-hydroxy-8,10-heptadecatrienoic acid; HHT, 12L-hydroxy-5,8,10-heptadecatrienoic acid; L-8027, 2-isopropyl-3-nicotinylindole; N-0164, *p*-benzyl-4-[1-oxo-2-(4-chlorobenzyl)-3-phenylpropyl]phenyl phosphonate; PG, prostaglandin; TLC, thin-layer chromatography; TX, thromboxane

*Present address. Department of Nephrology, Centre Hospitalier Universitaire, Sherbrooke, Quebec J1H 5N4, Canada

thromboxane synthase, [1-¹⁴C]PGH₁ (spec. act. 0.34 Ci/mol) and [1-¹⁴C]PGH₂ (spec. act. 1.0 Ci/mol) were prepared as described [2]. The endoperoxides moved slightly ahead of PGB₁ on silica gel G thin-layer chromatography (TLC) and were converted to PGF_{1 α} and PGF_{2 α} , respectively, by SnCl₂ reduction. 9 α ,11 α -Azo-15(S)hydroxyprosta-5(*cis*), 13(*trans*)-dienoic acid (APA) was generously given by Dr E. J. Corey. 9 α ,11 α -Epoxy-methano-15(S)hydroxyprosta-5(*cis*), 13(*trans*)-dienoic acid (EMPA) and TXB₂ were kindly provided by the Upjohn Company. 2-Isopropyl-3-nicotinylindole (L-8027) and sodium *p*-benzyl-4-[1-oxo-2-(4-chlorobenzyl)-3-phenylpropyl]phenyl phosphonate (N-0164) were given by Labaz and Nelson Research, respectively. Imidazole and SnCl₂ were purchased from Sigma.

2.1. Analyses of products formed from prostaglandin endoperoxides

Partially purified thromboxane synthase in 0.1 M Tris-HCl, pH 7.4, was incubated at 24°C with [1-¹⁴C]-PGH₁ (154 μ M) or [1-¹⁴C]PGH₂ (120 μ M). Reactions were interrupted after 1 min by addition of cold 0.2 M citric acid and products were immediately extracted with diethyl ether. After conversion to methyl esters aliquots were analyzed by TLC (solvent systems: (a) diethyl ether/methanol 49:1 v/v; (b) and (c) the organic phases of ethyl acetate/2,2,4-trimethylpentane/water 50:100:100 and 75:75:100 v/v/v, respectively). The remainder of the products was further converted to trimethylsilyl ether derivatives and analyzed by gas-liquid chromatography (1% OV-1) - mass spectrometry (GLC-MS).

2.2. Enzyme inhibition experiments

Incubations were performed at twice the scale described before [3]. Extracts were divided into two parts, for the determination of TXB_2 and HHT, respectively. Unlabeled TXB_2 was added as an internal reference for the former analyses. Methylated samples were analyzed by TLC using solvents (a) and (b) (section 2.1) for TXB_2 and HHT determinations, respectively.

Radioactivity on thin-layer chromatograms was determined as described [3].

2.3. Trapping of thromboxane A_2

Partially purified thromboxane synthase in 0.1 M Tris-HCl, pH 7.4, was incubated at 37°C with $[1-^{14}\text{C}]\text{PGH}_2$ (120 μM). Reactions were stopped after either 10 s or 2 min by the addition of 80 vol. methanol to convert TXA_2 to *O*-methyl TXB_2 [4]. After 1 h at 24°C, the methanol was removed in vacuo, water was added and the products were extracted with diethyl ether. Parallel incubations were stopped by adding 5 vol. SnCl_2 in ethanol (5 mg/ml) to reduce PGH_2 to $\text{PGF}_{2\alpha}$ [5]. In this case, products were extracted after 2 min at 24°C. Ether extracts were methylated and analyzed by TLC, using solvents (a–c) (section 2.1). For analyses with solvent (a), TXB_2 was added prior to methylation as an internal reference.

3. Results

3.1. Products formed from PGH_1 and PGH_2

Figure 1 shows thin-layer radiochromatograms of products isolated after incubations of $[1-^{14}\text{C}]\text{PGH}_1$ (upper panel) and $[1-^{14}\text{C}]\text{PGH}_2$ (lower panel) with purified thromboxane synthase from human platelets. Based on GLC-MS analyses the major product from the first incubation was identified as 2-hydroxy 8,10-heptadecadienoic acid (HHD; *C*-value 19.3; ions at *m/e* 368 (M), 353 (M-15, $\cdot\text{CH}_3$), 337 (M-31, $\cdot\text{OCH}_3$), 321 (M-15-32, $\cdot\text{CH}_3 + \text{CH}_3\text{OH}$), 297 (base peak, M-71, $\cdot\text{CH}_2(\text{CH}_2)_3\text{CH}_3$), 278 (M-90, $(\text{CH}_3)_3\text{SiOH}$) and 225 (M-143, $\cdot\text{CH}_2(\text{CH}_2)_5\text{COOCH}_3$). Small amounts of TXB_1 (*C*-value 24.9; ions at *m/e* 602 (M), 587 (M-15), 531 (M-71), 512 (M-90), 441 (M-71-90), 422 (M-2 \times 90), 368, 325, 301, 297, 258, 243 (base peak), 217 and 173) were also detected.




Fig.1. Thin-layer radiochromatograms of products formed from $[1-^{14}\text{C}]\text{PGH}_1$ (upper) and $[1-^{14}\text{C}]\text{PGH}_2$ (lower) during incubations (24°C, 1 min) with partially purified thromboxane synthase from human platelets. HHD, 12-hydroxy-8,10-heptadecadienoic acid; HHT, 12-hydroxy-5,8,10-heptadecatrienoic acid and TXB_2 , thromboxane B_2 (solvent (a), section 2.1.).

The two major products formed from PGH_2 were identified as 12-hydroxy-5,8,10-heptadecatrienoic acid (*C*-value 19.2; ions at *m/e* 366 (M), 351 (M-15), 335 (M-31), 319 (M-15-32), 295 (base peak, M-71), 276 (M-90) and 225 (M-141, $\text{CH}_2\text{CH}=\text{CH}(\text{CH}_2)_3\text{COOCH}_3$)) and TXB_2 (*C*-value 24.6; ions at *m/e* 600 (M), 585 (M-15), 529 (M-71), 510 (M-90), 439 (M-71-90), 420 (M-2 \times 90), 366, 323, 301, 295, 256 (base peak), 217 and 173), respectively.

3.2. Inhibition of thromboxane B_2 , HHT and HHD formation

In a previous study data were presented on the inhibition of thromboxane synthase by several compounds [3]. The most potent inhibitors, APA, EMPA, L-8027, N-0164 and imidazole, were selected for the present investigation. Human platelet microsomes were incubated with $[1-^{14}\text{C}]\text{PGH}_2$ in the presence of the inhibitors. Two dose-inhibition curves were deter-




Fig.2. Linear regression of the inhibition of thromboxane B₂ and HHT formation by L-8027 (Δ), N-0164 (\circ), imidazole (\square), 9 α ,11 α -epoxymethano-15(S)-hydroxyprosta-5(*cis*), 13(*trans*)-dienoic acid (\bullet) and 9 α ,11 α -azo-15(S)hydroxyprosta-5(*cis*), 13(*trans*)-dienoic acid (\blacktriangledown).

mined for each substance, one for TXB₂ and one for HHT formation. For a given inhibitor these curves were always nearly identical. Analogous experiments with [1-¹⁴C]PGH₁ as substrate also gave similar dose-inhibition curves for HHT formation. In fig.2 the inhibition of TXB₂ formation has been plotted against the inhibition of HHT formation for all five inhibitors. Linear regression gave a slope of 0.99, an intercept of 1.38 and a coefficient of determination of 0.96.

3.3. Exclusive transformation of TXA₂ to TXB₂

PGH₂ was incubated with partially purified thromboxane synthase for either 10 s or 2 min at 37°C. The reactions were stopped by addition of excess methanol to convert TXA₂ to *O*-methyl TXB₂. Parallel incubations, stopped by addition of SnCl₂ in ethanol, showed that no endoperoxide remained after 10 s incubation. At this time the reaction mixture contained 21% TXA₂ (measured as *O*-methyl TXB₂) 22% TXB₂ and 55% HHT (fig.3, upper). After 2 min incubation the products consisted of < 3% TXA₂, 42% TXB₂ and 55% HHT (fig.3, lower).




Fig.3. Thin-layer radiochromatograms of products formed from [1-¹⁴C]PGH₂ during incubations with partially purified thromboxane synthase at 37°C for 10 s (upper) and 2 min (lower). Incubations were stopped by the addition of 80 vol. methanol, to convert thromboxane A₂ to *O*-methyl thromboxane B₂ (O-Me TXB₂) (Solvent (c), section 2.1.).

4. Discussion

HHT was earlier detected as a by-product of prostaglandin biosynthesis in sheep vesicular gland [6]. It was suggested to be formed from a prostaglandin endoperoxide. The other product of the reaction was identified as malondialdehyde [6]. It was later found that HHT and TXB₂ were formed by aggregating human platelets in approximately equal amounts [7]. During previous studies on the solubilization and purification of platelet thromboxane synthetase we observed that HHT was enzymically formed from PGH₂ by the same fractions that formed TXB₂ [2]. Furthermore, the purified enzyme converted PGH₁ predominantly to HHT (fig.1). Five structurally unrelated inhibitors of thromboxane formation [3] inhibited TXB₂ and HHT formation from PGH₂ identically (fig.2) and in addition inhibited HHT formation from PGH₁. These results strongly suggest that platelet thromboxane synthase catalyzes the conversion of prostaglandin endoperoxides to C₁₇ hydroxy acids plus malondial-




Fig.4. Possible mechanism of thromboxane A₂ (TXA₂), HHT and malondialdehyde (MDA) formation from PGH₂, catalyzed by thromboxane synthase.

dehyde. This reaction might or might not involve thromboxane A as an intermediate. TXA₂ was generated during a short incubation of PGH₂ with purified thromboxane synthase and the products formed during its spontaneous decay were determined (fig.3). The results showed that TXA₂ was exclusively transformed to thromboxane B₂ and that HHT was formed independently. This is consistent with the predominant formation of HHD from PGH₁ and the approx. 1:1 formation of TXB₂ and HHT from PGH₂

(fig.1). A hypothetical reaction mechanism is outlined in fig.4. It is postulated that the isomerization of PGH to thromboxane A is initiated by protonation of the oxygen at C-9 of the substrate. The cation formed after cleavage of the O-O bond can rearrange in two ways to yield either thromboxane A or C₁₇ hydroxy acid plus malondialdehyde. The results showing that TXA₂ is exclusively converted to TXB₂ has important implications for the quantitative determination of thromboxane synthesis in various biological systems.

Acknowledgements

This work was supported by a grant from the Swedish Medical Research Council (project 03X-217).

References

- [1] Samuelsson, B. (1977) in: Proc. 1976 Intra-Science Symposium, Raven Press, Santa Monica, CA USA, in press
- [2] Hammarström, S. and Falardeau, P. (1977) Proc. Natl. Acad. Sci. USA 74, 3691-3695.
- [3] Diczfalusy, U. and Hammarström, S. (1977) FEBS Lett. 82, 107-110.
- [4] Hamberg, M., Svensson, J. and Samuelsson, B. (1975) Proc. Natl. Acad. Sci. USA 72, 2994-2998.
- [5] Hamberg, M. and Samuelsson, B. (1973) Proc. Natl. Acad. Sci. USA 70, 899-903.
- [6] Hamberg, M. and Samuelsson, B. (1967) J. Biol. Chem. 242, 5344-5354.
- [7] Hamberg, M., Svensson, J. and Samuelsson, B. (1974) Proc. Natl. Acad. Sci. USA 71, 3824-3828.